A trial looking at taladegib for small cell lung cancer

Cancer type:

Lung cancer
Secondary cancers
Small cell lung cancer




Phase 1/2

This trial looked at taladegib (LY2940680) with carboplatin and etoposide chemotherapy for small cell lung cancer. It was for people whose cancer had spread beyond the lungs.  

It was open for people to join between 2013 and 2014. The team analysed the results in 2018. There are links to more information in the ‘Summary of results’ section below.

More about this trial

Small cell lung cancer (SCLC) that has spread within the chest or to another part of the body is called extensive disease. Doctors usually treat extensive disease with chemotherapy. When this trial was done, they often used a combination of carboplatin and etoposide

Taladegib is a type of targeted cancer treatment called a cancer growth blocker. It stops signals that cancer cells use to divide and grow.

There were two parts to this trial. 

In part 1, everyone had carboplatin and etoposide chemotherapy and taladegib capsules. They had various doses of taladegib.

In part 2, people were due to have either:

  • carboplatin and etoposide with taladegib capsules
  • carboplatin and etoposide with dummy (placebo) capsules

But the trial was closed earlier than planned, before part 2 started. 

The main aims of this trial were to find out:

  • the best dose of taladegib to give with carboplatin and etoposide
  • how well taladegib, carboplatin and etoposide works for extensive stage small cell lung cancer
  • more about the side effects

Summary of results

We aim to add a lay summary of results to all the trials on our database. Unfortunately we have not been able to include a summary for this one.

There is more information about the results in the links below.

Please note, the information we link to here is not in plain English. It has been written for healthcare professionals and researchers.

A Study of LY2940680 in Small Cell Lung Cancer

National Library of Medicine - https://clinicaltrials.gov/
Accessed March 2024

Clinical Trial Results: A Phase 1b/2 Double-Blind Randomized Trial of the Hedgehog/SMO Antagonist LY2940680 in Combination with Carboplatin and Etoposide Followed by LY2940680 versus Carboplatin and Etoposide Plus Placebo Followed by Placebo in Patients with Extensive-Stage Small Cell Lung Cancer

EU Clinical Trials Register - https://www.clinicaltrialsregister.eu/ 
Accessed March 2024

Recruitment start:

Recruitment end:

How to join a clinical trial

Please note: In order to join a trial you will need to discuss it with your doctor, unless otherwise specified.

Please note - unless we state otherwise in the summary, you need to talk to your doctor about joining a trial.

Chief Investigator

Dr Martin Forster

Supported by

Eli Lilly and Company Limited
Experimental Cancer Medicine Centre (ECMC)
NIHR Clinical Research Network: Cancer

If you have questions about the trial please contact our cancer information nurses

Freephone 0808 800 4040

Last review date

CRUK internal database number:

Oracle 10666

Please note - unless we state otherwise in the summary, you need to talk to your doctor about joining a trial.

Last reviewed:

Rate this page:

No votes yet
Thank you!
We've recently made some changes to the site, tell us what you think